We are developing a platform of entirely novel small molecules to address the most significant unmet needs in cancer medicine. Our molecules cross the blood brain barrier and exhibit minimal toxicity.
Our lead compound targets tumours with severely disordered energy metabolism (around 30% of all cancers) and shows efficacy in KRAS-driven human cancer cells (among other oncogenic drivers) with minimal side effects.
Our second compound has the potential to revolutionise cancer chemotherapy by increasing DNA binding of cancer drugs. This has the potential to improve the wellbeing of up to 2 million cancer patients a year worldwide.
Our pipeline also includes a compound to amplify the effect of radiotherapy of all modalities.
Our lead compound targets tumours with severely disordered energy metabolism (around 30% of all cancers) and shows efficacy in KRAS-driven human cancer cells (among other oncogenic drivers) with minimal side effects.
Our second compound has the potential to revolutionise cancer chemotherapy by increasing DNA binding of cancer drugs. This has the potential to improve the wellbeing of up to 2 million cancer patients a year worldwide.
Our pipeline also includes a compound to amplify the effect of radiotherapy of all modalities.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Spain
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Ag5
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
